ALFA Finder| Revenue growth | 15% YoY growth in Q1 FY27. |
|---|---|
| Margins | Gross margin improved to 33% from 30% YoY. |
| Demand visibility | Cyclical; H2 generally stronger for regulated markets due to winter season. |
| Management confidence | High on long-term value from new product platforms and integration. |
Growth
Revenue increased from INR 263Cr to INR 304Cr; EBITDA improved from INR 10Cr to INR 25Cr YoY.
Outlook
Commissioning 7-ACA project (INR 750Cr capex) and Cefiderocol by March 2027; targeting global Exblifep expansion.
Risks
Industry facing overcapacities and cutthroat pricing pressure; regional conflict in Middle East impacting commercial rollouts.
Last quarter's promises, checked
Delivered
- Guided 10-15% base growth → delivered 15% YoY (= BEAT)
- Guided Q4 gross margin recovery → delivered 33% vs 30% YoY (= BEAT)
- Guided 7-ACA commissioning Q1CY27 → delivered On Track (= BEAT)
Partly delivered
- Guided Exblifep US deal closure Q1/Q2 → delivered advanced stages (= PARTIAL)
Missed
- Guided licensing deal every quarter → delivered zero new deals (= MISS)
Investor Presentation filed with BSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹877.00
- Market cap
- ₹5,252 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 605.9×Sector 43.8×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Board Meeting Date
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.